Editas to cut 65% of workforce, officially stops work on ex vivo sickle cell therapynews2024-12-12T22:09:20+00:00December 12th, 2024|Endpoints News|
Genetic medicine startups Chroma, Nvelop merge into nChromanews2024-12-11T12:00:50+00:00December 11th, 2024|Endpoints News|
#ASH24: Arcellx and Gilead seek to unseat J&J/Legend in multiple myelomanews2024-12-10T02:28:02+00:00December 10th, 2024|Endpoints News|
#ASH24: Beam shares results from seven patients who received gene-edited sickle cell therapynews2024-12-09T03:10:43+00:00December 9th, 2024|Endpoints News|
FDA is looking into hematology risks after patients take Bluebird’s Skysona gene therapynews2024-11-27T19:44:30+00:00November 27th, 2024|Endpoints News|
Updated: Roche buys out CAR-T partner Poseida for $1B upfrontnews2024-11-26T11:41:03+00:00November 26th, 2024|Endpoints News|
Patient dies in Neurogene’s Rett syndrome studynews2024-11-21T22:30:12+00:00November 21st, 2024|Endpoints News|
#ACR24: Bristol Myers takes on autoimmune diseases with cell therapy; New data from Cabaletta and Kyvernanews2024-11-19T15:52:02+00:00November 19th, 2024|Endpoints News|
Rocket shares promising long-term results from rare heart disease gene therapy in small studynews2024-11-18T20:31:08+00:00November 18th, 2024|Endpoints News|
Neurogene patient had life-threatening side effect in Rett syndrome studynews2024-11-18T19:55:48+00:00November 18th, 2024|Endpoints News|
